|
|
Volumn 94, Issue 5, 2002, Pages 326-328
|
|
Biotech firm faces challenges from FDA, falling stock prices
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
GEMCITABINE;
IRINOTECAN;
PACLITAXEL;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL STUDY;
COLORECTAL CANCER;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG BINDING;
DRUG INDUSTRY;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HEAD AND NECK CANCER;
HUMAN;
LAW SUIT;
LUNG NON SMALL CELL CANCER;
METASTASIS;
NOTE;
PANCREAS CANCER;
PRIORITY JOURNAL;
PROGNOSIS;
SOLID TUMOR;
|
|
EID: 0037029101
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.5.326 Document Type: Note |
|
Times cited : (14)
|
|
References (0)
|